Who is sponsoring NCT02287129?

NCT02287129 is sponsored by Technical University of Munich.

What drugs are being tested in NCT02287129?

Interventions in NCT02287129: Oxaliplatin, Epirubicin, Capecitabine, 5-FU, Carboplatin, Paclitaxel, radiation, Biopsy.

What condition does NCT02287129 study?

NCT02287129 studies Adenocarcinoma of the Esophagogastric Junction.

Is NCT02287129 still recruiting?

NCT02287129 is currently completed. Last updated 28 November 2023.

Last reviewed 2023-11-28 · How we verify

NCT02287129: MEMORI

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

Completed Phase 2 Last updated 28 November 2023

What this trial tests

Phase 2 trial testing Oxaliplatin in Adenocarcinoma of the Esophagogastric Junction in 75 participants. Completed in 7 August 2020.

Timeline

5 December 2014

Primary endpoint
7 August 2020

7 August 2020

Quick facts

Lead sponsor	Technical University of Munich
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	75
Start date	5 December 2014
Primary completion	7 August 2020
Estimated completion	7 August 2020
Sites	1 location across Germany

Drugs / interventions tested

Oxaliplatin (Oxaliplatin) — full drug profile →
Epirubicin (EPIRUBICIN) — full drug profile →
Capecitabine (capecitabine) — full drug profile →
5-FU
Carboplatin
Paclitaxel — full drug profile →
radiation
Biopsy

Conditions studied

Adenocarcinoma of the Esophagogastric Junction — all drugs for Adenocarcinoma of the Esophagogastric Junction →

Sponsor

Technical University of Munich

Who can join

18 and older, any sex, with Adenocarcinoma of the Esophagogastric Junction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Metabolic and Molecular Response evaluation for the individualization of therapy in adenocarcinomas of the gastroesophageal junction by evaluation of the R0 resection rate for patients with metabolically (ie, according to PET criteria) chemotherapy-resistant locally advanced AEG, who receive an intensified neoadjuvant chemoradiotherapy (INRCT). Additonal efforts will be done by investigation of molecular and metabolic biomarkers in relation to their predictive and prognostic value by correlating them with histopathologic responses and clinical outcome in an exploratory approach.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.
Pol J, Vacchelli E, Aranda F, Castoldi F, et al · · 2015 · cited 238× · PMID 26137404 · DOI 10.1080/2162402x.2015.1008866
UEG Week 2021 Oral Presentations
· 2021

Verify or expand the search:

Other trials of Oxaliplatin

Trials testing the same drug.

NCT07365306 — Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant · Phase 2 · not yet recruiting
NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07415031 — A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies · Phase 2 · not yet recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07340567 — Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test · Phase 3 · not yet recruiting

Other recruiting trials for Adenocarcinoma of the Esophagogastric Junction

Currently open trials in the same condition.

NCT06681298 — A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastr · Phase 2 · active not recruiting

Other Technical University of Munich trials

Trials by the same sponsor.

NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
NCT06650995 — AlEX-DHF: Ablation and Exercise in Diastolic Heart Failure · NA · recruiting
NCT07077005 — Mavacamten Enables Exercise in Hypertrophic Obstructive Cardiomyopathy · NA · recruiting
NCT07212699 — Development of an Outcome Score for Patients With Knee Osteoarthritis and Knee Joint Endoprosthesis Using an App · NA · recruiting
NCT06823271 — Haemodynamics and Ventricular Arrhythmias During Exercise in Patients With Arrhythmogenic Cardiomyopathy · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02287129 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Technical University of Munich
Last refreshed: 28 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02287129.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing